Posted from: Monday, April 06, 2015 - 10:04 AM - Present

Eylea Approved for Diabetic Retinopathy

March 25, 2015 – The U.S. Food and Drug Administration (FDA) approved Eylea (aflibercept) for intravitreal injection use to treat diabetic retinopathy in patients with diabetic macular edema (DME). Eylea is manufactured by Regeneron Pharmaceuticals.  Eylea was previously approved to treat neovascular age-related macular degeneration (wet AMD), macular edema following central retinal vein occlusion and DME. For diabetic retinopathy in patients with DME, Eylea will be used in each affected eye once a month for five months, followed by one injection every two months. After a local anesthetic and an anti-infective are applied, Eylea is injected inside the eye by a specially trained doctor in a sterile clinic or office. 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.


Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.


*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Wednesday, October 16, 2019 - 04:03 PM.